2025
A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts
Sosenko J, Cuthbertson D, Jacobsen L, Redondo M, Sims E, Ismail H, Herold K, Skyler J, Nathan B, Groups D. A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts. Diabetes Technology & Therapeutics 2025, 27: 179-186. PMID: 39757867, DOI: 10.1089/dia.2024.0422.Peer-Reviewed Original ResearchConceptsIndependent of insulin secretionArea under the curveAUC C-peptideAutoantibody-positive individualsC-peptideInsulin secretionAUC glucoseGlucose toleranceFirst-phase insulin responseDiabetes Prevention Trial-Type 1Type 1 diabetes progressionOral glucose tolerance test dataGlucose tolerance test dataPrediction of T1DImpaired glucose toleranceOral glucose toleranceType 1 diabetesDPT-1TrialNet PathwayIncreased glycemiaInsulin responseInverse correlationSecretionT1DLack of correlation
2023
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
Ramos E, Dayan C, Chatenoud L, Sumnik Z, Simmons K, Szypowska A, Gitelman S, Knecht L, Niemoeller E, Tian W, Herold K. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. New England Journal Of Medicine 2023, 389: 2151-2161. PMID: 37861217, DOI: 10.1056/nejmoa2308743.Peer-Reviewed Original ResearchConceptsC-peptide levelsB cell functionDiagnosed type 1 diabetesType 1 diabetesSecondary end pointsEnd pointsMild cytokine release syndromePeak C-peptide levelsMonoclonal antibodies to CD3Stimulated C-peptide levelsNewly diagnosed type 1 diabetesClinical type 1 diabetesCytokine release syndromePatients 8 yearsPlacebo-controlled trialPrimary end pointAntibodies to CD3Clinical end pointsAssociated with administrationPrevent disease progressionGlycated hemoglobin levelsFood and Drug AdministrationTarget glucose rangeT cellsTeplizumab
2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal Of Medicine 2019, 381: 603-613. PMID: 31180194, PMCID: PMC6776880, DOI: 10.1056/nejmoa1902226.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedCD3 ComplexChildDiabetes Mellitus, Type 1Disease ProgressionDouble-Blind MethodExanthemaFemaleGlucose Tolerance TestHLA-DR3 AntigenHLA-DR4 AntigenHumansLymphocyte CountLymphopeniaMaleMiddle AgedProportional Hazards ModelsT-LymphocytesYoung AdultConceptsType 1 diabetesClinical type 1 diabetesTeplizumab groupPlacebo groupOral glucose tolerance testInsulin-producing beta cellsDouble-blind trialChronic autoimmune diseaseGlucose tolerance testRelatives of patientsRate of diagnosisHigh-risk participantsTransient lymphopeniaAdverse eventsHazard ratioHLA-DR3HLA-DR4Median timeClinical progressionAutoimmune diseasesExogenous insulinCD3 antibodyT cellsTeplizumabClinical disease
2015
β Cell death and dysfunction during type 1 diabetes development in at-risk individuals
Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP. β Cell death and dysfunction during type 1 diabetes development in at-risk individuals. Journal Of Clinical Investigation 2015, 125: 1163-1173. PMID: 25642774, PMCID: PMC4362259, DOI: 10.1172/jci78142.Peer-Reviewed Original ResearchConceptsUnmethylated INS DNAINS DNARisk individualsType 1 diabetes developmentCell killingT1D-associated autoimmunityUnmethylated insulin DNADiagnosis of T1DHigh-risk subjectsAmerican Diabetes AssociationHealthy control subjectsJuvenile Diabetes Research FoundationPrimary pathologic processType 1 diabetesCell deathΒ-cell deathNonprogressor groupPeridiagnosis periodTrialNet PathwayBlood testsDiabetes AssociationDiabetes developmentIslet autotransplantMetabolic decompensationControl subjects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply